Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
Same author

Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registry.

Urology practice·2026
Same author

Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis.

Cancers·2026
Same author

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.

BJUI compass·2026
Same author

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

The Journal of urology·2026
Same author

Tumor-informed ctDNA surveillance after radical nephrectomy and level IV IVC thrombectomy for clear cell renal cell carcinoma: Early detection of molecular residual disease.

Urology case reports·2026
Same journal

Why Can Modulation of α6-Containing GABA<sub>A</sub> Receptors Reduce the Symptoms of Multiple Neuropsychiatric Disorders?

Archives of pharmacology and therapeutics·2024
Same journal

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.

Archives of pharmacology and therapeutics·2022
Same journal

<i>ProLungâ„¢-budesonide</i> Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation.

Archives of pharmacology and therapeutics·2021
Same journal

COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer.

Archives of pharmacology and therapeutics·2021
Same journal

Pharmacogenetic Variants in the <i>DPYD</i> and <i>TYMS</i> Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice.

Archives of pharmacology and therapeutics·2020
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K

Targeted Therapy in Non-Muscle Invasive Bladder Cancer-Clinical Updates.

Rachel Passarelli1, John Pfail1, David Golombos2

  • 1Division of Urology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA.

Archives of Pharmacology and Therapeutics
|September 18, 2025
PubMed
Summary
This summary is machine-generated.

Non muscle invasive bladder cancer (NMIBC) has high relapse rates. Precision medicine targeting genetic mutations offers promising new bladder-sparing therapies for NMIBC patients, with ongoing clinical trials underway.

Keywords:
Bladder cancerNon muscle invasive bladder cancerPrecision medicineTarget therapy

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.2K

Related Experiment Videos

Last Updated: Jan 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.2K

Area of Science:

  • Oncology
  • Urology
  • Genetics

Background:

  • Non muscle invasive bladder cancer (NMIBC) accounts for 75% of bladder cancer diagnoses.
  • Current treatments like chemotherapy and Bacillus Calmette-Guerin (BCG) have high relapse rates (40-50%) for high-risk patients.
  • Radical cystectomy, while recommended for high-risk NMIBC, involves high morbidity and is not suitable for all patients.

Purpose of the Study:

  • To review recent advances in targeted therapies for NMIBC.
  • To assess preliminary outcomes and ongoing clinical trials for precision medicine in NMIBC.
  • To anticipate the evolving treatment landscape for NMIBC.

Main Methods:

  • Conducted a literature review of PubMed and Medline (OVID) for studies on NMIBC targeted therapies.
  • Performed a search on clinicaltrials.gov for active NMIBC clinical trials.
  • Synthesized preliminary outcomes and trial data for targeted NMIBC treatments.

Main Results:

  • Preliminary data suggest promising outcomes for targeted therapies in NMIBC.
  • Numerous clinical trials are investigating targeted treatments, many in later stages.
  • Advances in understanding NMIBC molecular features are driving precision medicine approaches.

Conclusions:

  • Targeted therapies represent a growing area of research for NMIBC.
  • Precision medicine holds potential for more effective, bladder-sparing NMIBC treatments.
  • Upcoming research and trials are expected to significantly impact the NMIBC treatment paradigm.